{"id":"W3165241302","doi":"10.1016/s1470-2045(21)00151-0","title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":373,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Sorafenib; Bevacizumab; Atezolizumab; Internal medicine; Oncology; Hepatocellular carcinoma; Quality of life (healthcare); Response Evaluation Criteria in Solid Tumors; Clinical trial; Progression-free survival; Performance status; Cancer; Clinical endpoint; Phases of clinical research; Surgery; Chemotherapy; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001942469,0.001782079,0.00265507,0.0003116936,0.0003111371,0.001345305,0.0007513321,0.001613219,0.004965113],"category_scores_gemma":[0.002335178,0.0006286911,0.003645154,0.0003659735,0.001056343,0.001325977,0.0005836291,0.00364703,0.0008978957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009416564,"about_ca_system_score_gemma":0.0006685727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008564305,"about_ca_topic_score_gemma":0.001719359,"domain_scores_codex":[0.9992059,0.0004360877,0.00004746591,0.0001345644,0.00004683147,0.0001293205],"domain_scores_gemma":[0.9987448,0.0003825109,0.0003777953,0.0001015342,0.00006291601,0.0003303912],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.976787,0.002312198,0.001349385,0.000612547,0.002461333,0.00003235614,0.00005331005,0.0005250329,0.001135595,0.0001062928,0.0008181722,0.01380676],"study_design_scores_gemma":[0.9383819,0.05443957,0.003958068,0.00005635664,0.001398229,0.00005327554,0.00003674882,0.0005331836,0.0002660276,0.0002665129,0.0005824211,0.00002781225],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888449,0.005931923,0.0004875122,0.0008992575,0.0004630692,0.0008506147,0.001012477,0.00007443357,0.001435825],"genre_scores_gemma":[0.9920697,0.001963704,0.0007318628,0.0008282813,0.0003603901,0.001177762,0.001348984,0.00001878059,0.00150055],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004965113,"threshold_uncertainty_score":0.01661003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1298463038578968,"score_gpt":0.3448993800596667,"score_spread":0.2150530762017699,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}